Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Primatene Mist Availability Not “Essential,” Advisory Panel Says

This article was originally published in The Tan Sheet

Executive Summary

Questions about the appropriateness of asthma for OTC treatment led to an FDA advisory panel vote in favor of removing Wyeth's Primatene Mistfrom the market during a Jan. 24 meeting in Bethesda, Md
Advertisement

Related Content

Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Armstrong Wants Extra Year To Develop Inhaler Without Epinephrine
Primatene Mist To Be Unavailable After 2010 – Proposed Rule
NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
ONP: Leaner, Meaner In 2006
OTC Bronchodilators With Ephedrine Permitted In New Proposed Rule
OTC Asthma Inhaler Labeling "Strengthening" Called For By AMA
OTC Asthma Inhaler Labeling "Strengthening" Called For By AMA

Topics

Advertisement
UsernamePublicRestriction

Register

PS099053

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel